Christina Enke-Stolle

BioM AG is a regional technology transfer and venture capital services company created in 1997 following Munich's selection in the Government-sponsored BioRegio Competition. The firm provides business support services to Munich-based biotechnology companies, focusing on startups. Through BioM Biotech Cluster Development GmbH, established in 2006, BioM coordinates the Munich Biotech Cluster, with the objective of turning it into a leading biotechnology center in Europe. They seek to foster an active cooperation between Bavarian research institutions and corporations. BioM actively invests seed capital in biotechnology startups in the Munich area, and manages a venture capital investment fund invested in high-growth early-stage businesses.

Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany.

BIO Deutschland is a business association for the biotechnology industry. The private company is based in Berlin, Germany. The German company was founded by Peter Heinrich, Horst Domdey. Viola Bronsema has been the CEO of the company since 2006.

The Council of European Bioregions is a membership-based biotechnology organization. The Spanish company was founded by Horst Domdey.

GNA Biosolutions GmbH develops instruments for molecular pathogen detection. The firm offers PCA technology, lab and portable solutions. The company was founded by Joachim Stehr, Federico Bürsgens and Lars Ullerich in 2010 and is headquartered in Martinsried, Germany.

Part of Evotec SE, Evotec (München) GmbH is a German company that provides manufacturing and research support services for pharmaceutical and biotechnology companies. The company is based in Neuried, Germany. The CEOs are Dirk Ullmann, Loëtitia Edith Rouxel. The company was founded in 2005 by Axel Ullrich, Hellmut Kirchner, Henrik Daub. Evotec (München was acquired by Evotec SE on April 19, 2011 for $20.40 million.

conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany.